ValiRx Plc
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.valirx.com
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Dose Finding Safety Study of VAL201 in Cancer Patients
Phase 1
Completed
- Conditions
- Stage III Prostate CarcinomaStage IV Prostate Carcinoma
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- ValiRx Plc
- Target Recruit Count
- 12
- Registration Number
- NCT02280317
News
ValiRx Secures £16 Million Licensing Deal for Repurposed Risperidone Cancer Therapy VAL401
ValiRx PLC announced that Ambrose Healthcare Ltd has exercised its option to license VAL401, a reformulated risperidone with anti-cancer properties, for up to £16 million plus royalties.